CRISPR-Cas9 treatment partially restores amyloid-β 42/40 in human fibroblasts with the Alzheimer's disease PSEN1 M146L mutation

• Main Authors: Evangelos Konstantinidis (Author), Agnieszka Molisak (Author), Florian Perrin (Author), Linn Streubel-Gallasch (Author), Sarah Fayad (Author), Daniel Y. Kim (Author), Karl Petri (Author), Martin J. Aryee (Author), Ximena Aguilar (Author), Bence György (Author), Vilmantas Giedraitis (Author), J. Keith Joung (Author), Vikram Pattanayak (Author), Magnus Essand (Author), Anna Erlandsson (Author), Oksana Berezovska (Author), Martin Ingelsson (Author)
• Format: Book
• Published: Elsevier, 2022-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Presenilin 1 (PS1) is a central component of γ-secretase, an enzymatic complex involved in the generation of the amyloid-β (Aβ) peptide that deposits as plaques in the Alzheimer's disease (AD) brain. The M146L mutation in the PS1 gene (PSEN1) leads to an autosomal dominant form of early-onset A...